Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
BeOne Medicines
MOMA Therapeutics
Astellas Pharma Inc
Kestrel Therapeutics, Inc.
Institut Claudius Regaud
National Cancer Institute (NCI)
Astellas Pharma Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Plexium, Inc.
Eilean Therapeutics
Deciphera Pharmaceuticals, LLC
Revolution Medicines, Inc.
St. Justine's Hospital
M.D. Anderson Cancer Center
USWM, LLC (dba US WorldMeds)
ARTBIO Inc.
Coherus Oncology, Inc.
Suzhou Abogen Biosciences Co., Ltd.
Conjupro Biotherapeutics, Inc.
Modulation Therapeutics, Inc.
Alterome Therapeutics, Inc.
First Hospital of China Medical University
IDEAYA Biosciences
National Institutes of Health Clinical Center (CC)